ArticleIJU case reports2022

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib.

Koshiro Nishimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.